Senti Biosciences, INC. (SNTI) — 8-K Filings

All 8-K filings from Senti Biosciences, INC.. Browse 25 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (25)

Senti Biosciences Files 8-K — Apr 1, 2026 Risk: low
Senti Biosciences, Inc. filed an 8-K on April 1, 2026, to report other events. The filing does not contain specific financial figures or new material events bey
8-K Filing — Mar 27, 2026
8-K Filing — Dec 9, 2025
Senti Biosciences Files 8-K on Executive Changes — Jul 18, 2025 Risk: medium
Senti Biosciences, Inc. filed an 8-K on July 18, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment o
Senti Biosciences Reports on Shareholder Votes — Jun 30, 2025 Risk: low
Senti Biosciences, Inc. filed an 8-K on June 30, 2025, reporting on matters submitted to a vote of security holders as of June 25, 2025. The filing details the
Senti Biosciences Files 8-K — Jun 18, 2025 Risk: low
Senti Biosciences, Inc. filed an 8-K on June 18, 2025, to report an event under Regulation FD Disclosure and Other Events. The filing does not contain specific
Senti Biosciences Files 8-K on Financials and Operations — Apr 28, 2025 Risk: medium
Senti Biosciences, Inc. filed an 8-K on April 28, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD d
Senti Biosciences Enters Material Definitive Agreement — Mar 24, 2025 Risk: medium
On March 20, 2025, Senti Biosciences, Inc. entered into a material definitive agreement. The company, previously known as Dynamics Special Purpose Corp., is inc
Senti Biosciences Board Changes and Officer Compensation — Mar 10, 2025 Risk: medium
Senti Biosciences, Inc. announced on March 6, 2025, a change in its board of directors, with the departure of Dr. Philip P. Pesce and the appointment of Dr. Jon
Senti Biosciences Files 8-K on Shareholder Votes & Financials — Mar 7, 2025 Risk: low
Senti Biosciences, Inc. filed an 8-K on March 7, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing pertain
Senti Biosciences Files 8-K: Director Departs, Disclosures Made — Feb 25, 2025 Risk: medium
Senti Biosciences, Inc. announced on February 23, 2025, the departure of Director Dr. Philip P. Pescatore. The company also reported on compensatory arrangement
Senti Biosciences Reports Executive and Director Changes — Feb 6, 2025 Risk: medium
Senti Biosciences, Inc. filed an 8-K on February 6, 2025, reporting changes effective January 31, 2025. The filing details the departure of directors or certain
Senti Biosciences Files 8-K on Financial Obligations & Equity Sales — Jan 6, 2025 Risk: medium
On December 31, 2024, Senti Biosciences, Inc. filed an 8-K report detailing several key events. The company entered into a direct financial obligation and also
Senti Biosciences Files 8-K — Dec 16, 2024 Risk: low
On December 16, 2024, Senti Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
Senti Biosciences Files 8-K — Dec 3, 2024 Risk: low
Senti Biosciences, Inc. filed an 8-K on December 3, 2024, reporting other events and financial statements. The company, formerly known as Dynamics Special Purpo
Senti Biosciences Files 8-K — Dec 2, 2024 Risk: low
On December 2, 2024, Senti Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and a Regulation FD disclosur
Senti Biosciences Faces Delisting Notice — Oct 25, 2024 Risk: high
Senti Biosciences, Inc. filed an 8-K on October 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The earliest event rep
Senti Biosciences Enters Material Definitive Agreement — Sep 27, 2024 Risk: medium
On September 23, 2024, Senti Biosciences, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement or a
Senti Biosciences Files 8-K for Bylaw Amendments — Jul 17, 2024 Risk: low
Senti Biosciences, Inc. filed an 8-K on July 17, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, in
Senti Biosciences Enters Material Definitive Agreement — Jul 16, 2024 Risk: medium
On July 16, 2024, Senti Biosciences, Inc. filed an 8-K to report the entry into a material definitive agreement. The filing does not disclose specific details o
Senti Biosciences Files 8-K on Security Holder Matters — Jul 12, 2024 Risk: medium
Senti Biosciences, Inc. filed an 8-K on July 12, 2024, reporting on events that occurred on July 10, 2024. The filing indicates material modifications to the ri
Senti Biosciences Names New CEO, Board Changes — May 17, 2024 Risk: medium
Senti Biosciences, Inc. announced on May 14, 2024, a series of executive and board changes. Dr. Philip P. Sia has been appointed as the new Chief Executive Offi
Senti Bio Announces Leadership Changes — May 2, 2024 Risk: medium
Senti Biosciences, Inc. announced on April 26, 2024, the departure of Chief Medical Officer Dr. Philip Arlen and the election of Dr. Michael J. Yaszemski as a n
Senti Biosciences Faces Nasdaq Delisting for Low Bid Price — Feb 6, 2024
Senti Biosciences, Inc. (SNTI) announced on February 6, 2024, that it received a delisting notice from the Nasdaq Stock Market because its common stock failed t
Senti Biosciences Reports Exit/Disposal Activities on Jan 3 — Jan 5, 2024
Senti Biosciences, Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 3, 2024. This filing indicates that the company is undergoi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX